Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internat...
2522.HK opened lower at 4.50 HKD but staged a sharp intraday rebound, closing the morning session up 5.62% at 4.70 HKD, driven by a broader market recovery and improving fundamentals. The company reported a full-year net profit of 3.75 million RMB for 2025, turning around from losses, with Q4 revenue rising 22.37% YoY to 226 million HKD and net loss narrowing 73.33% to 7.06 million HKD. The stock initially touched a new 52-week low of 4.33 HKD (80.77% below the 52-week high of 24.44 HKD) before bouncing to the day's high of 4.70 HKD; total turnover was 2.35 million HKD on 517,500 shares traded (turnover rate 0.18%). Despite the rebound, the price remains below both the 20-day MA (4.947 HKD) and 60-day MA (6.098 HKD), with a YTD loss of 43.31% and a price-to-book ratio of 0.84x, though the company's trustee recently purchased 7.5 million shares on-market for a share award scheme, signaling insider confidence.
RIMAG Group (2522.HK) traded in a narrow range during the morning session, closing marginally up 0.6% at HKD 4.95, 79.8% below its 52-week high of HKD 24.44 and down 40.3% year-to-date. The stock hovered near the 5-day moving average but remained well below the 60-day MA of HKD 6.295, indicating a persistent weak long-term trend. On the news front, an on-market purchase of 7.5 million shares by a trustee for an award scheme signaled some insider confidence, while the company turned profitable for the full year 2025 with a net profit of RMB 3.75 million, and Q4 revenue rose 22.4% YoY to HKD 226 million with net loss narrowing 73.3%. However, the stock traded at a lofty PE of 471.6x and saw low turnover of just 1.13 million shares, reflecting thin liquidity.
Jiangxi Rimag closed down 0.8% at HKD 4.93 today, after briefly touching an intraday high of HKD 5.0 in the morning session, with the day's trading range between HKD 4.9 and 5.0. The decline was driven by renewed regulatory headwinds in the medical imaging sector, coupled with the company's ongoing turnaround despite improving fundamentals. While Q4 2025 revenue rose 22.37% YoY to HKD 225.8 million and net loss narrowed 73.33% YoY to HKD 7.06 million, the stock remains 79.83% below its 52-week high of HKD 24.44 and is down 40.53% year-to-date. TFI Asset Management reiterated a Buy rating but provided no specific target price. However, the stock's P/B ratio of 0.88x may attract value-oriented investors.
Jiangxi Yimaiyangguang Group Co., Ltd. opened lower and rebounded sharply in the morning session, surging from HKD 4.78 to HKD 5.17 within 15 minutes, an 8.39% gain from the previous close of HKD 4.77, on a thin volume of 500 shares and turnover of HKD 2,585. The company's Q4 FY2025 operating revenue of HKD 225.8 million rose 22.37% YoY, while net loss narrowed 73.33% to HKD 7.06 million, though EPS remained negative at HKD -0.0183. At HKD 5.17, the stock is 78.85% below its 52-week high of HKD 24.44 but 38.24% above its 52-week low of HKD 3.74, having breached the 20-day MA of HKD 5.007 while still trading well below the 60-day MA of HKD 6.633. The P/B ratio of 0.93x indicates a below-book valuation, and the P/E of 492.54x reflects weak profitability, though consecutive quarterly net loss narrowing by over 73% in both Q3 and Q4 provides a bottom-line improvement narrative.
2522.HK tumbled in the afternoon session, closing 5.61% lower at HKD 4.710, retreating 80.73% from its 52-week high of HKD 24.44 and posting a year-to-date decline of 43.18%. The stock briefly spiked to HKD 5.020 in the morning but then fell steadily, accelerating to an intraday low of HKD 4.710 in the afternoon with no late rebound, on total turnover of approximately HKD 5.52 million and a turnover rate of 0.39%. Recent news includes a trustee purchasing 7,501,000 shares on-market for a share award scheme, and a full-year net profit turnaround of RMB 3.75 million; however, the latest two quarters still show net losses albeit narrowing (Q4 net loss narrowed 73.33% YoY to about HKD 7.06 million), while revenue grew 22.37% YoY to HKD 225.78 million. The stock trades below its MA20 (HKD 5.012) and MA60 (HKD 6.685), with a PB of 0.84x and a high PE of 448.71x. Notably, the stock has rebounded about 25.94% from its 52-week low of HKD 3.74.
The Unbundling of Hong Kong's Equities: Value Chains in Specialized Tech and Industrials
HK Mid-Caps Show Divergent Trajectories as Biotech Advances While Retail Faces Headwinds
Star Plus Legend's Surge and Expressway's Cash: HK's Eclectic Mix
Jiangxi Rimag says trustee buys 7,501,000 shares on-market for share award scheme
TFI Asset Management Reaffirms Their Buy Rating on Jiangxi Rimag Group Co., Ltd. Class H (2522)
Jiangxi Rimag Outlines Board Line-up and Committee Roles